Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 6 min ago
Peer-reviewedLicence not statedBritish Journal of Cancer

LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation

  • Jiamei Guo1
  • Fenglin Cai2
  • Mengmeng Zhang3
  • Xinyang Nie1
  • Mingzhi Cai1
  • Feiyu Meng1
  • Xingyu Li1
  • Zixiang Wei1
  • Yi Yang
  • Rupeng Zhang1
  • Yikun Yao4
  • Yongzhan Nie5
1 more authors
  • Jingyu Deng1,6
6 affiliations
  1. 1Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin Key Laboratory of Digestive Cancer; Tianjin’s Clinical Research Center for Cancer, Tianjin, China
  2. 2Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, The First Clinical Medical College of Nanjing Medical University, Nanjing Medical University, Nanjing, China
  3. 3Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui China
  4. 4Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
  5. 5State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, Shaanxi China
  6. 6Present Address: Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China
Read full textDOICite

Related

  1. PTTG1 drives intestinal-type gastric cancer progression via G2/M checkpoint-mediated cell-cycle reprogramming
    Caihong Hu, Lijun Bian, Lin Luo +10
    iSciencePeer-reviewedCC BY-NC-NDFull textOncologyCell PressEurope PMCCrossref
  2. JARID2 promotes prostate cancer progression associated with TET3-mediated activation of the FAK/PI3K/AKT signaling pathway
    Jinrun Wang, Yang Liu, Yanze Li +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  3. Novel androgen receptor N-terminal mutation drives gastric cancer metastasis via YWHAZ-mediated FAK pathway activation
    Tianru Ben, Lingyu Zhou, Zonghao Liu +3
    Journal of Translational MedicinePeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  4. miR-4652-5p targets GFPT1 to suppress ATF6-mediated unfolded protein response (UPR) and UPR-driven apoptosis to drive gastric tumor progression
    Qingyu Zeng, Yangyuan Huang, Liping Li +5
    Cellular & Molecular Biology LettersPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  5. From inflammation to carcinogenesis: MiRNA regulates epithelial-mesenchymal transition to facilitate malignant progression of gastric precancerous lesions
    Yibing Tian, Tai Zhang, Bochao Yuan +3
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{guo2026lamb3,
  title = {{LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation}},
  author = {Jiamei Guo and Fenglin Cai and Mengmeng Zhang and Xinyang Nie and Mingzhi Cai and Feiyu Meng and Xingyu Li and Zixiang Wei and Yi Yang and Rupeng Zhang and Yikun Yao and Yongzhan Nie and Jingyu Deng},
  journal = {British Journal of Cancer},
  year = {2026},
  month = jun,
  doi = {10.1038/s41416-026-03496-w},
  url = {https://doi.org/10.1038/s41416-026-03496-w},
}
RIS
TY  - JOUR
TI  - LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation
AU  - Jiamei Guo
AU  - Fenglin Cai
AU  - Mengmeng Zhang
AU  - Xinyang Nie
AU  - Mingzhi Cai
AU  - Feiyu Meng
AU  - Xingyu Li
AU  - Zixiang Wei
AU  - Yi Yang
AU  - Rupeng Zhang
AU  - Yikun Yao
AU  - Yongzhan Nie
AU  - Jingyu Deng
PY  - 2026
DA  - 2026/06/17
JO  - British Journal of Cancer
DO  - 10.1038/s41416-026-03496-w
UR  - https://doi.org/10.1038/s41416-026-03496-w
SN  - 0007-0920
SN  - 1532-1827
ER  -